Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Interest Expenses (2017 - 2024)

Historic Interest Expenses for Neurocrine Biosciences (NBIX) over the last 7 years, with Q1 2024 value amounting to $1.1 million.

  • Neurocrine Biosciences' Interest Expenses changed 0.0% to $1.1 million in Q1 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year decrease of 6857.14%. This contributed to the annual value of $32.0 million for FY2019, which is 469.37% up from last year.
  • Neurocrine Biosciences' Interest Expenses amounted to $1.1 million in Q1 2024, which was down 0.0% from $1.1 million recorded in Q3 2023.
  • In the past 5 years, Neurocrine Biosciences' Interest Expenses ranged from a high of $8.5 million in Q3 2020 and a low of $1.1 million during Q1 2023
  • For the 4-year period, Neurocrine Biosciences' Interest Expenses averaged around $4.9 million, with its median value being $6.3 million (2021).
  • As far as peak fluctuations go, Neurocrine Biosciences' Interest Expenses surged by 625.0% in 2020, and later crashed by 2530.12% in 2021.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Interest Expenses stood at $8.5 million in 2020, then fell by 22.35% to $6.6 million in 2021, then plummeted by 83.33% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024.
  • Its Interest Expenses stands at $1.1 million for Q1 2024, versus $1.1 million for Q3 2023 and $1.3 million for Q2 2023.